CVSA vs ACAD
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
CVSA · Covista$110.32 ▼ 2.34%
ACAD · ACADIA Pharmaceuticals$21.23 ▼ 0.05%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- CVSA +15.9%
- ACAD -4.4%
Head to head
| Metric | CVSA | ACAD |
|---|---|---|
| Price | $110.32 | $21.23 |
| Change today | ▼ 2.34% | ▼ 0.05% |
| Market cap | $3.67B | $3.67B |
| Return, 3 months | -14.3% | -27.8% |
| Return, year to date | +6.6% | -20.5% |
| Return, 1 year | +16.3% | -5.9% |
| P/E (TTM) | 15.1 | 10.0 |
| P/B | 2.6 | 2.6 |
| P/E percentile vs own 5y | 48th | 58th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +10.7% | +16.4% |
| Net profit growth (YoY) | +9.0% | +18.1% |
| Gross margin | 57.4% | 91.1% |
| Operating margin | 20.1% | 7.6% |
| Net margin | 12.8% | 33.4% |
| Return on equity | 17.9% | 35.7% |
| Analyst target vs. price | +43.9% | +52.3% |
| Analyst buy share | 75% | 83% |
| RSI (14) | 27 | 52 |
| 30-day volatility | 38.0% | 32.3% |
| Max drawdown, 1 year | -42.0% | -39.1% |
| Trend read | Strong downtrend | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ACAD is the largest of the group by market value.
- CVSA has returned the most over the past year.
- ACAD carries the lowest trailing P/E.
- ACAD is growing revenue fastest.
- ACAD keeps the most profit per dollar of sales.
- ACAD has been the calmest stock over the last 30 days.